D3 Receptor Agonist Compounds; Methods of Preparation; Intermediates Thereof; and Methods of Use Thereof
Summary
EPO published patent application EP3953350A1 for D3 receptor agonist compounds filed by the United States Department of Health and Human Services. The patent covers specific chemical compounds, methods of preparation, intermediates thereof, and methods of therapeutic use.
What changed
EPO published patent application EP3953350A1 for D3 receptor agonist compounds filed by the US Department of Health and Human Services. The patent covers specific chemical compounds classified under C07D 413/14 and A61K 31/5377, along with methods of preparation, intermediates, and therapeutic uses. The application designates all EU member states.
For pharmaceutical companies developing receptor-targeted therapies, this patent publication establishes intellectual property rights that may affect freedom-to-operate analyses. Entities conducting research in D3 receptor agonist compounds should review the patent claims to assess potential licensing requirements or design-around considerations.
Archived snapshot
Apr 18, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF
Publication EP3953350A1 Kind: A1 Apr 08, 2026
Applicants
The United States of America, as Represented by
The Department of Health and Human Services
Inventors
HAUCK NEWMAN, Amy, BONIFAZI, Alessandro, BATTITI, Francisco, Oscar, CEMAJ, Sophie, L.
IPC Classifications
C07D 413/14 20060101AFI20201016BHEP A61K 31/5377 20060101ALI20201016BHEP A61P 25/00 20060101ALI20201016BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.